Merck
U.S. pharma major behind Keytruda, the world's top-selling cancer immunotherapy.
Coverage of Merck is holding steady : 4 signals on the latest tracked day, up 33% from its three-week baseline of 3, across 3 domains (down from 5 a week ago). That makes it the #228 most-covered of the 349 concerns we track.
What’s changed
- Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma · BioPharma Dive — Latest News · 2026-08-21
- Moderna/Merck news - what does it mean for the field, and what’s next? · Reddit r/biotech · 2026-08-20
- Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push · Reddit r/biotech · 2026-08-20
- Considering accepting Merck (Boston) offer · Reddit r/biotech · 2026-08-20
- STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial · STAT News — All Content · 2026-08-19
- Merck Canada Language Requirements · Reddit r/biotech · 2026-08-14
What the reporting says
Across 61 tracked stories from 26 outlets, reporting on Merck most often describes regulatory approvals (11), public statements (4), acquisition (2), launches or releases (2), IPOs or listings (1), elections (1).
It shows up alongside Moderna (24), Astrazeneca (13), FDA (21), Immunotherapy (21), AI (12), Bristol Myers Squibb (12), Eli Lilly (11), Drug Administration (8).
Two steps out: Abstract (through Immunotherapy, 21 shared stories on the weaker link); Cder (through FDA, 21 shared stories on the weaker link); Colorectal Cancer (through FDA, 21 shared stories on the weaker link); Drug Evaluation (through FDA, 21 shared stories on the weaker link).
Tracked since May 5, with coverage on 22 separate days — concentrated in Biotech Pharma.